Turmeric Acquisition Corp.
Status: Liquidated
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $97.75M |
|---|---|
| IPO Date | Oct 16, 2020 |
| CEO | Luke Evnin, Ph.D. |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology with an emphasis on oncology and rare disease therapeutics |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Oct 20, 2022 |
TMPM
TMPMU
TMPMW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Turmeric Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 11 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Matthew Roden, Ph.D. | 50 | Chairman |
| David Meeker, M.D. | 65 | Director |
| Andrew Robbins, M.B.A. | 44 | Director |
| Mitchell H. Finer, Ph.D. | 61 | Director |
| Pablo Cagnoni, M.D. | 57 | Director |
| Luke Evnin, Ph.D. | 57 | Chief Executive Officer |
| Todd Foley, M.B.A. | 48 | President |
| Ed Hurwitz, J.D., M.B.A. | 56 | Chief Financial Officer |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Credit Suisse | Joint BR | 6,587,500 | units |
| JMP Securities | Joint BR | 1,912,500 | |
| 8,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 11 filings.